SARASOTA, Fla., Oct. 19, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.: Diabetic Treatment Centers of America, Inc. (OTCBB:DBTC), Crucell N.V. (Nasdaq:CRXL), Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM).
Diabetic Treatment Centers of America, Inc. (OTCBB:DBTC), a company dedicated providing diabetics with significantly improved health and a better quality of life, announced after the bell Monday the execution of an exclusive rights agreement with Diabetes Medical Development Corporation. The company said that the Agreement, which was executed by both parties, provides certain exclusive rights to patented technologies that are used to treat diabetes and other metabolic disorders.
Arden Oliphant, President and CEO of Diabetic Treatment Centers of America, Inc. said, "This Agreement is a significant step in our plan to provide some of the most advanced and effective therapies available in the world to our patients. The therapies supported by these proven, patented technologies will greatly improve the quality of life for persons suffering from severe diabetes and other metabolic disorders."
Shares of DBTC closed Wednesday up 3 cents at $1.20 on the OTCBB.
Other Biotechnology Stocks in the News on Monday were:
Crucell N.V. (Nasdaq:CRXL)
Dutch Biotechnology company Crucell N.V. announced before the opening bell on Monday that it had signed a License agreement with animal health company, Merial, by which Merial would deploy Crucell's PER.C6 technology to develop and commercialize veterinary vaccines for foot-and-mouth disease.
The company stated that it would speed through the final development process of vaccines, since foot-and-mouth disease outbreaks are unpredictable and could happen unexpectedly. The foot-and-mouth disease is a highly communicable disease that affects swine, sheep, cattle, deer and other animals.
CRXL closed Monday at $9.09, up 24 cents.
Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM)
Biopharmaceutical company Peregrine Pharmaceuticals Inc. announced before the bell Monday the successful completion of its 3G4 antibody humanization project, developed for the recognition of phospholipid, phosphatidylserine by AERES Biomedical Ltd. The company stated that the antibody is part of Peregrine's Anti-Phospholipid Therapy platform technology, and that human or humanized monoclonal antibodies are ideal components of drugs that may be administered multiple times to individual patients because they would not be recognized as foreign by the patient's immune system.
PPHM closed Monday at $1.48, up 6 cents on volume of 476,484 shares.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-- PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
-- StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.
-- Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company". The company received compensation for newsletter services for Diabetic Treatment Centers of America. (Public Company). The compensation is forty thousand dollars from a non-affiliated third party, Reynolds Finance Inc. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.